体力活动与不同临床及TMPRSS2:ERG亚型前列腺癌风险的前瞻性研究
基于Health Professionals Follow-up Study中49160名40–75岁男性(1986–2012年,随访>90%),前瞻性分析体力活动与前列腺癌(PCa)风险的关系。结果显示总体力活动与总体PCa风险无显著关联;剧烈活动最高五分位者晚期PCa风险降低30%(HR 0.70,95%CI 0.53–0.92)、致死性PCa风险降低25%(HR 0.75,95%CI 0.59–0.94),且ER G阳性PCa风险降低(HR 0.71,95%CI 0.52–0.97)。
要点
- 剧烈体力活动最高五分位者晚期PCa风险降低30%(HR 0.70,95%CI 0.53–0.92)。
- 剧烈体力活动最高五分位者致死性PCa风险降低25%(HR 0.75,95%CI 0.59–0.94)。
- 剧烈活动与ER G阳性PCa风险降低相关(HR 0.71,95%CI 0.52–0.97),与ER G阴性无显著关联。
核心结论
- 剧烈体力活动与晚期和致死性前列腺癌风险降低相关。
- 剧烈体力活动与TMPRSS2:ERG阳性前列腺癌风险降低相关,提供新证据。
研究设计与样本
- 前瞻性队列研究,纳入Health Professionals Follow-up Study中49160名40–75岁男性,1986–2012年随访,随访率>90%。
- 体力活动以代谢当量(MET)-h/wk测量,TMPRSS2:ERG通过ER G蛋白免疫组化评估,采用Cox比例风险模型计算多变量HR和95%CI。
主要发现
- 随访26年,6411例发生PCa,888例发生致死性疾病。
- 总体力活动与总体PCa风险无显著关联。
- 剧烈活动最高vs最低五分位:晚期PCa HR 0.70(95%CI 0.53–0.92),致死性PCa HR 0.75(95%CI 0.59–0.94),独立于筛查史。
- 剧烈活动与总体PCa在整体队列无显著关联,但在高度筛查男性中呈负相关(HR 0.83,95%CI 0.70–0.97)。
- 945例检测ER G(48%阳性),剧烈活动最高vs最低五分位与ER G阳性PCa风险降低相关(HR 0.71,95%CI 0.52–0.97),与ER G阴性无显著关联(异质性p=0.09)。
临床怎么用
- 对于咨询前列腺癌预防的男性,可建议进行剧烈体力活动以降低晚期和致死性前列腺癌风险。
- 剧烈体力活动可能特别降低TMPRSS2:ERG阳性前列腺癌风险,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Growing evidence shows that clinical and molecular subtypes of prostate cancer (PCa) have specific risk factors. Observational studies suggest that physical activity may lower the risk of aggressive PCa. To our knowledge, the association between physical activity and PCa defined by TMPRSS2:ERG has not been evaluated. OBJECTIVE: To prospectively examine the association between physical activity and risk of PCa defined by clinical features and TMPRSS2:ERG. DESIGN, SETTING, AND PARTICIPANTS: We studied 49160 men aged 40-75 yr in the Health Professionals Follow-up Study from 1986 to 2012. Data was collected at baseline and every 2 yr with >90% follow-up. Total and vigorous physical activity were measured in metabolic equivalent of task (MET)-h/wk. OUTCOME MEASURES AND STATISTICAL ANALYSIS: Advanced PCa was defined as stage T3b, T4, N1, or M1 at diagnosis and lethal PCa as distant metastases or death due to disease over follow-up. Presence of TMPRSS2:ERG was estimated by immunohistochemistry of ERG protein expression. Cox proportional hazards models were used to obtain multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of subtype-specific PCa. RESULTS AND LIMITATIONS: During 26 yr of follow-up, 6411 developed PCa overall and 888 developed lethal disease. There were no significant associations between total physical activity and risk of PCa in the overall cohort. In multivariable-adjusted models, men in the highest quintile of vigorous activity had a significant 30% lower risk of advanced PCa (HR: 0.70, 95% CI: 0.53-0.92) and 25% lower risk of lethal PCa (HR: 0.75, 95% CI: 0.59-0.94) than men in the lowest quintile of vigorous activity. The association was independent of screening history. Vigorous activity was not associated with total PCa in the overall cohort but was inversely associated among highly screened men (top vs bottom quintile, HR: 0.83, 95% CI: 0.70-0.97). Of all cases, 945 were assayed for ERG (48% ERG-positive). Men with higher vigorous activity had a lower risk of ERG-positive PCa (top vs bottom quintile, HR: 0.71, 95% CI: 0.52-0.97). There was no significant association with the risk of ERG-negative disease (p heterogeneity=0.09). CONCLUSIONS: Our study confirms that vigorous physical activity is associated with lower risk of advanced and lethal PCa and provides novel evidence for a lower risk of TMPRSS2:ERG-positive disease. PATIENT SUMMARY: The identification of modifiable lifestyle factors for prevention of clinically important prostate cancer (PCa) is needed. In this report, we compared risk of PCa in men with different levels of physical activity. Men with higher vigorous activity had a lower risk of developing advanced and lethal PCa and PCa with the common TMPRSS2:ERG gene fusion.
引用
- Pernar CH, Ebot EM, Pettersson A, et al. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur Urol. 2018. PMID: 30301696. doi:10.1016/j.eururo.2018.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。